Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Pharmaceutical
Yaneth Giha, the first woman to serve as executive director of FIFARMA, the Latin American Federation of the Pharmaceutical Industry, spoke to Angel Galindo, The Pharma Letter’s Latin America correspondent. 1 September 2022
Pharmaceutical
An Expert View from Steve Lendaris, partner at Baker Botts. 31 August 2022
Generics
It was not so very long ago that Indian drugmakers were facing headwinds due to the spike in prices of active pharmaceutical ingredients (APIs) and intermediates being imported from China. From being dependent on China for APIs in the past, India has now swung to the opposite end of the spectrum and is imposing anti-dumping duties on several APIs and key starting materials that come from China, reports The Pharma Letter’s India correspondent. 30 August 2022
Biotechnology
The annual meeting of the European Society of Medical Oncology (ESMO) kicks off in Paris on September 9, and early indications are the event could be full of practice-changing data. In the runup to the event, The Pharma Letter spoke with medical oncologist and ESMO Council member Antonio Passaro for an inside look at some of the leading themes and key presentations at the event. 29 August 2022
Biotechnology
In just three months, Henlius’ heavily invested PD1 blockbuster Hansizhuang (serplulimab) rewarded the company with nearly 80 million renminbi ($11.6 million) since its launch in March 2022 in China to treat microsatellite instability-high (MSI-H). 27 August 2022
Pharmaceutical
The accelerated approval pathway (AAP), which was first introduced by the US Food and Drug Administration (FDA) in 1992 to tackle the HIV epidemic, enables expedited development and approval of new therapies for serious diseases that lack efficient treatment options.1,2 26 August 2022
Biotechnology
August is spinal muscular atrophy (SMA) awareness month – an opportunity to reflect on the current and future treatment landscape. 25 August 2022
Pharmaceutical
Global drugmakers have significantly reduced their investments and payments into Russia and its pharmaceutical market this year due to the ongoing military conflict between Ukraine and Russia and sanctions imposed on the latter, reports The Pharma Letter’s local correspondent. 23 August 2022
Pharmaceutical
COVID-19 has changed the world during the past couple of years, and one of its lasting legacies will be the need for speed and agility in all spheres of healthcare. 22 August 2022
Generics
As generic drugmakers are dragged to court by patent holders and the cost of litigation soars for both generic as well as innovative pharma companies, many are settling patent disputes out of court. Generic companies often agree to delay their entry into the market in exchange for certain benefits, such as licenses to other patents, reports The Pharma Letter’s India correspondent. 16 August 2022
Pharmaceutical
An Expert View from Emer Leahy, chief executive, and Dani Brunner, chief innovation officer, of PsychoGenics, on the challenges involved in tackling mental disorders. 15 August 2022
Pharmaceutical
Amid the ongoing military conflict between Ukraine and Russia and the ever-tightening sanctions pressure on Russia, the Kremlin is considering investing about 200 billion roubles ($12.1 billion) in the achievement of so-called medicine and pharmaceutical sovereignty. 12 August 2022
Biosimilars
Russian drugmaker Biocad is eyeing becoming the largest supplier of oncology drugs for state needs, achieving this by producing analogues of some popular drugs for the treatment of cancer. 11 August 2022
Pharmaceutical
The outbreak of coronavirus disease (COVID-19) has brought the issue of localization to the forefront, which necessitated the need for localization of pharmaceutical manufacturing to achieve self-sufficiency and self-reliance, writes The Pharma Letter's local correspondent. 8 August 2022
Pharmaceutical
A feature on renewed interest in an area where the difficulty for drugmakers is matched only by the potential rewards. 3 August 2022
Pharmaceutical
Scientists at the Russian Granov Scientific Center for Radiology and Surgical Technologies have developed a new drug, which could be recommended for the use against severe forms of cancer, reports The Pharma Letter’s local correspondent. 2 August 2022
Pharmaceutical
Having been retained on the US Trade Representative's (USTR's) Priority Watch List alongside six other countries, the Indian government has undertaken an intellectual property review exercise to assess the risks to innovation and economic growth as posed by the USTR, reports The Pharma Letter’s India correspondent. 1 August 2022
Biotechnology
Amicus Therapeutics chairman and chief executive John Crowley and the company's general manager for the UK and Ireland, Charlie Galvin, provide an Expert View on the importance of the pact in ensuring the biotech industry meets its commitments to share the value of innovation with patients, protect health system budgets, and ensure sustainable access. 28 July 2022
Pharmaceutical
For Fragile X Awareness Month, we reflect on the current and future treatment landscape. 28 July 2022
Pharmaceutical
Combination therapies comprise two or more different types of medical products, including drugs, devices, and biological products.1 These individual components of combination therapies are called constituent parts, which might be physically or chemically combined and produced as a single entity (single entity combination product), packaged together as one unit (co-packaged combination product), or distributed separately (cross-labeled combination product).2 27 July 2022
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze